Literature DB >> 25410860

A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.

Mariana Baz1, Myeisha Paskel1, Yumiko Matsuoka1, James Zengel2, Xing Cheng2, John J Treanor3, Hong Jin2, Kanta Subbarao4.   

Abstract

UNLABELLED: Equine influenza viruses (EIV) are responsible for rapidly spreading outbreaks of respiratory disease in horses. Although natural infections of humans with EIV have not been reported, experimental inoculation of humans with these viruses can lead to a productive infection and elicit a neutralizing antibody response. Moreover, EIV have crossed the species barrier to infect dogs, pigs, and camels and therefore may also pose a threat to humans. Based on serologic cross-reactivity of H3N8 EIV from different lineages and sublineages, A/equine/Georgia/1/1981 (eq/GA/81) was selected to produce a live attenuated candidate vaccine by reverse genetics with the hemagglutinin and neuraminidase genes of the eq/GA/81 wild-type (wt) virus and the six internal protein genes of the cold-adapted (ca) A/Ann Arbor/6/60 (H2N2) vaccine donor virus, which is the backbone of the licensed seasonal live attenuated influenza vaccine. In both mice and ferrets, intranasal administration of a single dose of the eq/GA/81 ca vaccine virus induced neutralizing antibodies and conferred complete protection from homologous wt virus challenge in the upper respiratory tract. One dose of the eq/GA/81 ca vaccine also induced neutralizing antibodies and conferred complete protection in mice and nearly complete protection in ferrets upon heterologous challenge with the H3N8 (eq/Newmarket/03) wt virus. These data support further evaluation of the eq/GA/81 ca vaccine in humans for use in the event of transmission of an equine H3N8 influenza virus to humans. IMPORTANCE: Equine influenza viruses have crossed the species barrier to infect other mammals such as dogs, pigs, and camels and therefore may also pose a threat to humans. We believe that it is important to develop vaccines against equine influenza viruses in the event that an EIV evolves, adapts, and spreads in humans, causing disease. We generated a live attenuated H3N8 vaccine candidate and demonstrated that the vaccine was immunogenic and protected mice and ferrets against homologous and heterologous EIV.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25410860      PMCID: PMC4300743          DOI: 10.1128/JVI.02449-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.

Authors:  Brian R Murphy; Kathleen Coelingh
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

2.  Human responses to experimental infection with influenza A/Equi 2 virus.

Authors:  R H Alford; J A Kasel; J R Lehrich; V Knight
Journal:  Am J Epidemiol       Date:  1967-07       Impact factor: 4.897

Review 3.  Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.

Authors:  Robert Belshe; Min-Shi Lee; Robert E Walker; Jeffrey Stoddard; Paul M Mendelman
Journal:  Expert Rev Vaccines       Date:  2004-12       Impact factor: 5.217

4.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Authors:  Ruth A Karron; Karen Callahan; Catherine Luke; Bhagvanji Thumar; Josephine McAuliffe; Elizabeth Schappell; Tomy Joseph; Kathleen Coelingh; Hong Jin; George Kemble; Brian R Murphy; Kanta Subbarao
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

5.  Isolation and molecular characterization of equine H3N8 influenza viruses from pigs in China.

Authors:  Jiagang Tu; Hongbo Zhou; Taozhen Jiang; Chun Li; Anding Zhang; Xuebo Guo; Wei Zou; Huanchun Chen; Meilin Jin
Journal:  Arch Virol       Date:  2009-04-26       Impact factor: 2.574

6.  STUDIES OF ANTIBODIES TO 1956 AND 1963 EQUINE INFLUENZA VIRUSES IN HORSES AND MAN.

Authors:  E MINUSE; J L MCQUEEN; F M DAVENPORT; T FRANCIS
Journal:  J Immunol       Date:  1965-04       Impact factor: 5.422

7.  Experimental infection in man and horses with influenza A viruses.

Authors:  J A Kasel; R B Couch
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

8.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

9.  Isolation and characterization of H3N8 equine influenza A virus associated with the 2011 epizootic in Mongolia.

Authors:  Myagmarsukh Yondon; Gary L Heil; John P Burks; Batsukh Zayat; Thomas B Waltzek; Bekh-Ochir Jamiyan; Pamela P McKenzie; Whitney S Krueger; John A Friary; Gregory C Gray
Journal:  Influenza Other Respir Viruses       Date:  2013-01-04       Impact factor: 4.380

10.  Transmission of equine influenza virus to English foxhounds.

Authors:  Janet M Daly; Anthony S Blunden; Shona Macrae; Jodi Miller; Samantha J Bowman; Jolanta Kolodziejek; Norbert Nowotny; Ken C Smith
Journal:  Emerg Infect Dis       Date:  2008-03       Impact factor: 6.883

View more
  7 in total

1.  A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.

Authors:  Mariana Baz; Myeisha Paskel; Yumiko Matsuoka; James R Zengel; Xing Cheng; John J Treanor; Hong Jin; Kanta Subbarao
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

2.  Refining the approach to vaccines against influenza A viruses with pandemic potential.

Authors:  Rita Czako; Kanta Subbarao
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

Review 3.  A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies.

Authors:  Raj K Singh; Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Ashok Munjal; Sandip K Khurana; Sandip Chakraborty; Yashpal S Malik; Nitin Virmani; Rajendra Singh; Bhupendra N Tripathi; Muhammad Munir; Johannes H van der Kolk
Journal:  Front Microbiol       Date:  2018-09-06       Impact factor: 5.640

4.  Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic.

Authors:  Jannie Pedersen; Ismaël Hervé Koumakpayi; Giorgi Babuadze; Mariana Baz; Oumar Ndiaye; Oumar Faye; Cheikh Tidiane Diagne; Ndongo Dia; Maedeh Naghibosadat; Allison McGeer; Samira Muberaka; Irène P Moukandja; Stella Ndidi; Carlos B Tauil; Jean-Bernard Lekana-Douki; Cheikh Loucoubar; Ousmane Faye; Amadou Sall; Kelly G Magalhães; Nina Weis; Robert Kozak; Gary P Kobinger; Hugues Fausther-Bovendo
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

5.  Generation and protective efficacy of a cold-adapted attenuated avian H9N2 influenza vaccine.

Authors:  Yandi Wei; Lu Qi; Huijie Gao; Honglei Sun; Juan Pu; Yipeng Sun; Jinhua Liu
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

6.  Pathology of Equine Influenza virus (H3N8) in Murine Model.

Authors:  Selvaraj Pavulraj; Bidhan Chandra Bera; Alok Joshi; Taruna Anand; Meenakshi Virmani; Rajesh Kumar Vaid; Karuppusamy Shanmugasundaram; Baldev Raj Gulati; K Rajukumar; Rajendra Singh; Jyoti Misri; Raj Kumar Singh; Bhupendra Nath Tripathi; Nitin Virmani
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

7.  Development of a novel equine influenza virus live-attenuated vaccine.

Authors:  Laura Rodriguez; Stephanie Reedy; Aitor Nogales; Pablo R Murcia; Thomas M Chambers; Luis Martinez-Sobrido
Journal:  Virology       Date:  2018-01-11       Impact factor: 3.616

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.